Seeing, Thinking, Acting Different: Wittgenstein"s Language Games\ud and Bateson"s News of Difference in Therapeutic Narratives

Ever since R.Rorty published The Linguistic Turn in 1967,\ud the study of narrative has acquired new consideration. For\ud postmodern philosopher J-F. Lyotard the very advances of\ud science are seen "as anything more than a narrative and\ud not one that can override all others� (Lyotard, 1984, 16).\ud In the last two decades the attention of scholars has\ud focused upon the ability of narrative of modelling our\ud concepts of legitimacy and reality (Bruner, 2002, 124). The\ud dimension of narrative and that of narrating about oneself\ud is not only what constitutes our peculiar way of being\ud humans, but the privilege means by which we make order\ud in our lives and experiences and this also emphasizes the\ud therapeutic side of narration

An epistemological approach to psychiatry

n/

Oxidation of Long Chain Fatty Acids by Rat Liver Mitochondria

Abstract Long chain fatty acids are oxidized by rat liver mitochondria provided that endogenous adenosine triphosphate is not depleted. If endogenous ATP is depleted, e.g. by 2,4-dinitrophenol, external ATP as well as carnitine is required for fatty acid oxidation. Atractyloside does not block this reaction in media containing orthophosphate buffer. Oligomycin can substitute for carnitine, but the oligomycin-dependent route is inhibited by atractyloside. These experimental situations localize two ATP-dependent fatty acid-activating systems, one of which is linked to carnitine. The dinitrophenol-insensitive, GTP-specific fatty acyl coenzyme A synthetase is active only in the absence of orthophosphate. Inhibition of oxidation of fatty acids by atractylate in phosphate-free media is not relieved with oligomycin or carnitine

A Guanosine Triphosphate-dependent Acyl Coenzyme A Synthetase from Rat Liver Mitochondria

A guanosine triphosphate-specific acyl coenzyme A synthetase has been purified from extracts of sonically disrupted rat liver mitochondria. This enzyme, which is free of adenosine triphosphate-dependent activating systems and from succinyl-CoA synthetase activity, catalyzes the formation of CoA esters of both long and short chain fatty acids. GTP-specific fatty acid activation is inhibited by orthophosphate and fluoride

Fructose-1, 6-diphosphate (FDP) as a novel antidote for yellow oleander-induced cardiac toxicity: A randomized controlled double blind study

BACKGROUND: Cardiac toxicity due to ingestion of oleander plant seeds in Sri Lanka and some other South Asian countries is very common. At present symptomatic oleander seed poisoning carries a mortality of 10% in Sri Lanka and treatment of yellow oleander poisoning is limited to gastric decontamination and atropine administration. The only proven effective antidote is digoxin antibodies but these are not available for routine use because of the high cost. The main objective of this study is to investigate the effectiveness of a new and inexpensive antidote for patients with life threatening arrhythmias due oleander poisoning. METHOD/DESIGN: We set up a randomised double blind clinical trial to assess the effectiveness of Fructose 1, 6 diphosphate (FDP) in acute yellow oleander poisoning patients admitted to the adult medical wards of a tertiary hospital in Sri Lanka. Patients will be initially resuscitated following the national guidelines and eligible patients will be randomised to receive either FDP or an equal amount of normal saline. The primary outcome measure for this study is the sustained reversion to sinus rhythm with a heart rate greater than 50/min within 2 hours of completion of FDP/placebo bolus. Secondary outcomes include death, reversal of hyperkalaemia on the 6, 12, 18 and 24 hour samples and maintenance of sinus rhythm on the holter monitor. Analysis will be on intention-to-treat. DISCUSSION: This trial will provide information on the effectiveness of FDP in yellow oleander poisoning. If FDP is effective in cardiac glycoside toxicity, it would provide substantial benefit to the patients in rural Asia. The drug is inexpensive and thus could be made available at primary care hospitals if proven to be effective. TRIAL REGISTRATION: Current Controlled trial ISRCTN71018309

ENTRE LA DISCIPLINE ET LA CURE

"Critique", numéro spécial (Présence de Foucault), n. 696, mai 200